Glaukos Corporation $GKOS is Atika Capital Management LLC's 9th Largest Position

Key Points

• Atika Capital Management LLC increased its stake in Glaukos Corporation by 10.0%, now holding 263,500 shares valued at approximately $25.9 million, making it the fund's 9th largest position.
• Institutional investors comprise 99.04% of Glaukos' stock ownership, with several funds, including Wellington Management Group and Westfield Capital Management, also increasing their shares during the first quarter.
• Glaukos reported a revenue increase of 29.7% year-over-year in its latest earnings, surpassing analysts' expectations, yet posted a loss per share of ($0.24), with a projected EPS of -1.08 for the current year.

Atika Capital Management LLC boosted its holdings in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 10.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 263,500 shares of the medical instruments supplier's stock after buying an additional 24,000 shares during the quarter. Glaukos accounts for about 3.6% of Atika Capital Management LLC's portfolio, making the stock its 9th largest holding. Atika Capital Management LLC owned about 0.46% of Glaukos worth $25,934,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GKOS. Bessemer Group Inc. grew its position in Glaukos by 133.9% during the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after buying an additional 158 shares during the period. Whipplewood Advisors LLC raised its stake in shares of Glaukos by 3,957.1% in the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 277 shares during the period. First Horizon Advisors Inc. raised its stake in shares of Glaukos by 72.9% in the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after acquiring an additional 159 shares during the period. Versant Capital Management Inc raised its stake in shares of Glaukos by 583.9% in the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after acquiring an additional 327 shares during the period. Finally, CoreCap Advisors LLC lifted its position in shares of Glaukos by 36.4% during the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Wall Street Analyst Weigh In

GKOS has been the subject of several analyst reports. Morgan Stanley lowered their price target on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. UBS Group boosted their price target on shares of Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. William Blair upgraded shares of Glaukos to a "strong-buy" rating in a report on Thursday, July 31st. Stifel Nicolaus lowered their price target on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Finally, Mizuho set a $130.00 price target on shares of Glaukos in a report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $127.42.

Glaukos Stock Down 2.5%

GKOS stock traded down $2.37 during midday trading on Monday, reaching $91.78. 565,413 shares of the company were exchanged, compared to its average volume of 948,649. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. Glaukos Corporation has a 1-year low of $77.10 and a 1-year high of $163.71. The stock's 50-day simple moving average is $96.26 and its 200 day simple moving average is $100.70. The company has a market cap of $5.26 billion, a price-to-earnings ratio of -55.62 and a beta of 0.78.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company had revenue of $124.12 million for the quarter, compared to analysts' expectations of $115.49 million. During the same quarter last year, the company earned ($0.52) earnings per share. The firm's revenue for the quarter was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.